Most unknown people bought a UPS as suggest by some one or dealer/retailer.However its a matter of concern for your pocket becoz if your UPS is not completing your PC's Requirement . You are in Trouble.
I will Tell You Briefly , How to measure the capacity of UPS & PC .
this tech note helps explain the differences between Watts and VA and explains how the terms are correctly and incorrectly used in specifying power protection equipment. Many people are confused about the distinction between the Watt and Volt-Amp (VA) measures for UPS load sizing. Many manufacturers of UPS and load equipment add to this confusion by failing to distinguish between these measures. If you have arrived at this site in an attempt to be a more informed buyer of UPS or other power equipment, congratulations. Please feel free to email me at gurbinder.sharma@gmail.com so that I may assist you in selecting the correct equipment. Power Solutions is an independent supplier of power quality products offering the best in class solutions.
Background : The power drawn by computing equipment is expressed in Watts or Volt-Amps (VA). The power in Watts is the real power drawn by the equipment. Volt-Amps are called the "apparent power" and are the product of the voltage applied to the equipment times the current drawn by the equipment. Both Watt and VA ratings have a use and purpose. The Watt rating determines the actual power purchased from the utility company and the heat loading generated by the equipment. The VA rating is used for sizing wiring and circuit breakers. The VA and Watt ratings for some types of electrical loads, like incandescent light bulbs, are identical. However, for computer equipment the Watt and VA ratings can differ significantly, with the VA rating always being equal to or larger than the Watt rating. The ratio of the Watt to VA rating is called the "Power Factor" and is expressed either as a number (i.e. 0.7) or a percentage (i.e. 70%). We can assist you with proper UPS sizing if you provide us with either, total equipment VA, total equipment Watts, or a list of the equipment part numbers that you would like to back up. The Watt rating for a computer may not be equal to the VA rating . All Information Technology equipment including computers uses an electronic switching power supply. There are two basic types of computer switching power supplies, which are called 1) Power Factor Corrected supplies or 2) Capacitor Input supplies. It is not possible to tell which kind of power supply is used by inspection of the equipment, and this information is not commonly provided in equipment specifications. Power Factor Corrected or PFC supplies were introduced in the mid 1990's and have the characteristic that the Watt and VA ratings are equal (power factor of 0.99 to 1.0). Capacitor Input supplies have the characteristic that the Watt rating is in the range of .55 to .75 times the VA rating (power factor of 0.55 to 0.75).
All large computing equipment such as routers, switches, drive arrays, and servers made after about 1996 uses the Power Factor Corrected supply and consequently for this type of equipment the power factor is 1. Personal computers, small hubs, and personal computer accessories typically have Capacitor Input supplies and consequently for this type of equipment the power factor is less than one, and is ordinarily in the range of 0.65. Larger computer equipment made prior to 1996 also typically used this type of power supply and exhibited a power factor less than one.
The power rating of the UPS
UPS have both maximum Watt ratings and maximum VA ratings. Neither the Watt nor the VA rating of a UPS may be exceeded. It is a de-facto standard in the industry that the Watt rating is approximately 60% of the VA rating for small UPS systems, this being the typical power factor of common personal computer loads. In some cases, UPS manufacturers only publish the VA rating of the UPS. For small UPS designed for computer loads, which have only a VA rating, it is appropriate to assume that the Watt rating of the UPS is 60% of the published VA rating. For larger UPS systems, it is becoming common to focus on the Watt rating of the UPS, and to have equal Watt and VA ratings for the UPS, because the Watt and VA ratings of the typical loads are equal.
Examples where a sizing problem can occur
Consider this case: A typical 1000VA UPS. The user wants to power a 900W heater with the UPS. The heater has a Watt rating of 900W and a VA rating of 900VA with a power factor of 1. Although the VA rating of the load is 900VA, which is within the VA rating of the UPS, the UPS will probably not power this load. That is because the 900W rating of the load exceeds the Watt rating of the UPS, which is most likely 60% of 1000VA or around 600W.
How to avoid sizing errors :Equipment nameplate ratings are often in VA, which makes it difficult to know the Watt ratings. If using equipment nameplate ratings for sizing, a user might configure a system, which appears to be correctly sized based on VA ratings but actually exceeds the UPS Watt rating. By sizing the VA rating of a load to be no greater than 60% of the VA rating of the UPS, it is impossible to exceed the Watt rating of the UPS. Therefore, unless you have high certainty of the Watt ratings of the loads, the safest approach is to keep the sum of the load nameplate ratings below 60% of the UPS VA rating. Note that this conservative sizing approach will typically give rise to an oversized UPS and a larger run time than expected. If optimization of the system and an accurate run time are required, mail me on abobe mentioned mail Address. I Might have the ability to accurately size your UPS.
Conclusion : Power consumption information on computer loads is often not specified in a way that allows simple sizing of a UPS. It is possible to configure systems that appear to be correctly sized but actually overload the UPS. By slightly over sizing the UPS compared with the nameplate ratings of the equipment, proper operation of the system is ensured. Over sizing also provides the side benefit of providing additional UPS backup time. However, to truly ensure that your UPS is sized properly and that you do not waste money and space on an over-sized unit. So Mail me if you want any guidence for free.
Regards
Gurbinder
Tuesday, January 18, 2011
Monday, November 1, 2010
WHAT IS LATUDA
Important information about Latuda
Elderly people with dementia-related psychosis (a severe mental health problem) taking atypical
antipsychotic drugs, including Latuda, are at an increased risk for death compared with those
taking placebo (sugar tablet). Latuda is not approved for the treatment of people with
dementia-related psychosis (see BOXED WARNING). An increased risk for stroke and ministroke has
been reported in elderly people with dementia-related psychosis.
Neuroleptic malignant syndrome (NMS): NMS is a rare and potentially fatal side effect reported
with Latuda and similar medicines. Call your healthcare provider right away if you have high
fever; stiff muscles; confusion; changes in pulse, heart rate, or blood pressure; sweating; or
muscle pain and weakness. Treatment should be stopped if you have NMS.
Tardive dyskinesia (TD): TD is a serious and sometimes permanent side effect reported with
Latuda and similar medicines. TD includes uncontrollable movements of the face, tongue, and
other parts of the body. The risk for developing TD and the chance that it will become
permanent is thought to increase the longer a person takes the medicine and the more medicine a
person takes over time. TD can develop after a person has been taking the medicine for a short
time at low doses, although this is much less common. There is no known treatment for TD, but
it may go away partially or completely if the person stops taking the medicine.
High blood sugar: High blood sugar and diabetes have been reported with Latuda. In studies,
most people taking Latuda had no problems with their blood sugar. If you have diabetes or risk
factors for diabetes, such as being overweight or a family history of diabetes, your blood
sugar should be tested at the beginning of and throughout treatment with Latuda. Complications
of diabetes can be serious and even life threatening. Tell your healthcare provider if you have
blood sugar problems or signs of diabetes, such as being thirsty all the time, going to the
bathroom a lot, or feeling weak or hungry.
Weight gain: Some patients may gain weight while taking Latuda. Your healthcare provider should
check your weight regularly. Talk to your healthcare provider about ways to help control your
weight, such as eating a healthy, balanced diet and exercising.
Additional Important Warnings
Light-headedness or faintness caused by a sudden change in heart rate and blood pressure when
rising quickly from a sitting position has been reported with Latuda.
Low white blood cell counts and related conditions have been reported with Latuda and similar
medicines. Tell your healthcare provider if you have or had low white blood cell counts.
Latuda and medicines like it may raise the levels of prolactin. Tell your healthcare provider
if you experience a lack of menstrual periods, leaking or enlarged breasts, or impotence.
Tell your healthcare provider if you have a seizure disorder, have had seizures in the past, or
have conditions that increase your risk for seizures.
Tell your healthcare provider if you experience prolonged, abnormal muscle spasm or
contraction, which may be signs of a condition called dystonia.
Latuda can affect your judgment, thinking, and motor skills. You should not drive or operate
hazardous machinery until you know how Latuda affects you.
Latuda may make you more sensitive to heat. You may have trouble cooling off. Be careful when
exercising or when doing things likely to cause dehydration or make you warm.
The symptoms of schizophrenia may include thoughts of suicide or of hurting yourself or others.
If you have these thoughts at any time, tell your healthcare provider or go to an emergency
room right away.
Latuda and medicines like it have been associated with swallowing problems. If you have had or
have swallowing problems, you should tell your healthcare provider.
Pregnancy: Tell your healthcare provider if you are pregnant or if you are planning to get
pregnant while taking Latuda. Breast feeding is not recommended during treatment with Latuda.
Tell your healthcare provider about all prescription and over-the-counter medicines you are
taking or plan to take, since there are some risks for drug interactions with Latuda. Do not
drink alcohol while taking Latuda.
In people with schizophrenia, the most common side effects that occurred with Latuda were
sleepiness, an inner sense of restlessness or need to move (akathisia), uncontrolled movements
of the body and face (parkinsonism), upset stomach, and agitation.
This is not a complete summary of safety information. Please discuss the full Prescribing
Information for prescription Latuda with your doctor.
You are encouraged to report me gurbinder.sharma@gmail.com
How should I take Latuda?
Take Latuda exactly as prescribed by your doctor. Do not take in larger or smaller amounts or
for longer than recommended. Follow the directions on your prescription label.
Latuda should be taken with food.
Take Latuda regularly to get the most benefit. Get your prescription refilled before you run
out of medicine completely.
It may take several weeks before your symptoms improve. Keep using the medication as directed
and tell your doctor if your symptoms do not improve.
Store Latuda at room temperature away from moisture, light, and heat.
What happens if I miss a dose?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for
your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Overdose symptoms may include drowsiness, fast heart rate, feeling light-headed, fainting, and
restless muscle movements in your eyes, tongue, jaw, or neck.
What should I avoid while taking Latuda?
While you are taking Latuda, you may be more sensitive to temperature extremes such as very hot
or cold conditions. Avoid getting too cold, or becoming overheated or dehydrated. Drink plenty
of fluids, especially in hot weather and during exercise. It is easier to become dangerously
overheated and dehydrated while you are taking Latuda.
Latuda can cause side effects that may impair your thinking or reactions. Be careful if you
drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can
increase some of the side effects of Latuda.
Latuda side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives;
difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking Latuda and
call your doctor at once if you have a serious side effect such as:
fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled shaking);
fever, chills, body aches, flu symptoms;
trouble swallowing; or
feeling light-headed, fainting.
increased thirst or urination, weakness
Less serious Latuda side effects may include:
mild restlessness,agitiation, drowsiness, or tremor;
sleepiness, dreaming more than usual;
blurred vision;
abdominal pain;
dizziness or headache;
weight gain;
problems with urination;
nausea, diarrhea;
decreased appetite;
excessive salivation;
rash or itching
This is not a complete list of side effects and others may occur. Call your doctor for medical
advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Latuda Dosing Information
The recommended starting dose of Latuda is 40 mg once daily. The maximum recommended dose is 80
mg once daily. Latuda should be taken with food.
What other drugs will affect Latuda?
Before you take Latuda, tell your doctor if you regularly use other medicines that make you
sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle
relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused
by Latuda.
Also tell your doctor if you are taking any of the following medicines:
ketoconazole (Nizoral);
diltiazem (Cardizem, Dilacor);
rifampin (Rifadin, Rimactane, Rifater);
This list is not complete and other drugs may interact with Risperdal. Tell your doctor about
all medications you use. This includes prescription, over-the-counter, vitamin, and herbal
products. Do not start a new medication without telling your doctor.
Where can I get more information?
Your pharmacist can provide more information about Latuda.
gurbinder
My MedNotes
Get Updates by Email
Email me: gurbinder.sharma@gmail.com
Latuda side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives;
difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking Latuda and
call your doctor at once if you have a serious side effect such as:
fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled shaking);
fever, chills, body aches, flu symptoms;
trouble swallowing; or
feeling light-headed, fainting.
increased thirst or urination, weakness
Less serious Latuda side effects may include:
mild restlessness,agitiation, drowsiness, or tremor;
sleepiness, dreaming more than usual;
blurred vision;
abdominal pain;
dizziness or headache;
weight gain;
problems with urination;
nausea, diarrhea;
decreased appetite;
excessive salivation;
rash or itching
This is not a complete list of side effects and others may occur. Call your doctor for medical
advice about side effects. You may report side effects to http://cchrint.org
Latuda Dosing Information
The recommended starting dose of Latuda is 40 mg once daily. The maximum recommended dose is 80
mg once daily. Latuda should be taken with food.
What other drugs will affect Latuda?
Before you take Latuda, tell your doctor if you regularly use other medicines that make you
sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle
relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused
by Latuda.
Also tell your doctor if you are taking any of the following medicines:
ketoconazole (Nizoral);
diltiazem (Cardizem, Dilacor);
rifampin (Rifadin, Rimactane, Rifater); These drugs are for TB patient as well HIV /AIDS
This list is not complete and other drugs may interact with Risperdal. Tell your doctor about
all medications you use. This includes prescription, over-the-counter, vitamin, and herbal
products. Do not start a new medication without telling your doctor.
Where can I get more information?
www.cchrint.org
Your pharmacist can provide more information about Latuda.
Elderly people with dementia-related psychosis (a severe mental health problem) taking atypical
antipsychotic drugs, including Latuda, are at an increased risk for death compared with those
taking placebo (sugar tablet). Latuda is not approved for the treatment of people with
dementia-related psychosis (see BOXED WARNING). An increased risk for stroke and ministroke has
been reported in elderly people with dementia-related psychosis.
Neuroleptic malignant syndrome (NMS): NMS is a rare and potentially fatal side effect reported
with Latuda and similar medicines. Call your healthcare provider right away if you have high
fever; stiff muscles; confusion; changes in pulse, heart rate, or blood pressure; sweating; or
muscle pain and weakness. Treatment should be stopped if you have NMS.
Tardive dyskinesia (TD): TD is a serious and sometimes permanent side effect reported with
Latuda and similar medicines. TD includes uncontrollable movements of the face, tongue, and
other parts of the body. The risk for developing TD and the chance that it will become
permanent is thought to increase the longer a person takes the medicine and the more medicine a
person takes over time. TD can develop after a person has been taking the medicine for a short
time at low doses, although this is much less common. There is no known treatment for TD, but
it may go away partially or completely if the person stops taking the medicine.
High blood sugar: High blood sugar and diabetes have been reported with Latuda. In studies,
most people taking Latuda had no problems with their blood sugar. If you have diabetes or risk
factors for diabetes, such as being overweight or a family history of diabetes, your blood
sugar should be tested at the beginning of and throughout treatment with Latuda. Complications
of diabetes can be serious and even life threatening. Tell your healthcare provider if you have
blood sugar problems or signs of diabetes, such as being thirsty all the time, going to the
bathroom a lot, or feeling weak or hungry.
Weight gain: Some patients may gain weight while taking Latuda. Your healthcare provider should
check your weight regularly. Talk to your healthcare provider about ways to help control your
weight, such as eating a healthy, balanced diet and exercising.
Additional Important Warnings
Light-headedness or faintness caused by a sudden change in heart rate and blood pressure when
rising quickly from a sitting position has been reported with Latuda.
Low white blood cell counts and related conditions have been reported with Latuda and similar
medicines. Tell your healthcare provider if you have or had low white blood cell counts.
Latuda and medicines like it may raise the levels of prolactin. Tell your healthcare provider
if you experience a lack of menstrual periods, leaking or enlarged breasts, or impotence.
Tell your healthcare provider if you have a seizure disorder, have had seizures in the past, or
have conditions that increase your risk for seizures.
Tell your healthcare provider if you experience prolonged, abnormal muscle spasm or
contraction, which may be signs of a condition called dystonia.
Latuda can affect your judgment, thinking, and motor skills. You should not drive or operate
hazardous machinery until you know how Latuda affects you.
Latuda may make you more sensitive to heat. You may have trouble cooling off. Be careful when
exercising or when doing things likely to cause dehydration or make you warm.
The symptoms of schizophrenia may include thoughts of suicide or of hurting yourself or others.
If you have these thoughts at any time, tell your healthcare provider or go to an emergency
room right away.
Latuda and medicines like it have been associated with swallowing problems. If you have had or
have swallowing problems, you should tell your healthcare provider.
Pregnancy: Tell your healthcare provider if you are pregnant or if you are planning to get
pregnant while taking Latuda. Breast feeding is not recommended during treatment with Latuda.
Tell your healthcare provider about all prescription and over-the-counter medicines you are
taking or plan to take, since there are some risks for drug interactions with Latuda. Do not
drink alcohol while taking Latuda.
In people with schizophrenia, the most common side effects that occurred with Latuda were
sleepiness, an inner sense of restlessness or need to move (akathisia), uncontrolled movements
of the body and face (parkinsonism), upset stomach, and agitation.
This is not a complete summary of safety information. Please discuss the full Prescribing
Information for prescription Latuda with your doctor.
You are encouraged to report me gurbinder.sharma@gmail.com
How should I take Latuda?
Take Latuda exactly as prescribed by your doctor. Do not take in larger or smaller amounts or
for longer than recommended. Follow the directions on your prescription label.
Latuda should be taken with food.
Take Latuda regularly to get the most benefit. Get your prescription refilled before you run
out of medicine completely.
It may take several weeks before your symptoms improve. Keep using the medication as directed
and tell your doctor if your symptoms do not improve.
Store Latuda at room temperature away from moisture, light, and heat.
What happens if I miss a dose?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for
your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Overdose symptoms may include drowsiness, fast heart rate, feeling light-headed, fainting, and
restless muscle movements in your eyes, tongue, jaw, or neck.
What should I avoid while taking Latuda?
While you are taking Latuda, you may be more sensitive to temperature extremes such as very hot
or cold conditions. Avoid getting too cold, or becoming overheated or dehydrated. Drink plenty
of fluids, especially in hot weather and during exercise. It is easier to become dangerously
overheated and dehydrated while you are taking Latuda.
Latuda can cause side effects that may impair your thinking or reactions. Be careful if you
drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can
increase some of the side effects of Latuda.
Latuda side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives;
difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking Latuda and
call your doctor at once if you have a serious side effect such as:
fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled shaking);
fever, chills, body aches, flu symptoms;
trouble swallowing; or
feeling light-headed, fainting.
increased thirst or urination, weakness
Less serious Latuda side effects may include:
mild restlessness,agitiation, drowsiness, or tremor;
sleepiness, dreaming more than usual;
blurred vision;
abdominal pain;
dizziness or headache;
weight gain;
problems with urination;
nausea, diarrhea;
decreased appetite;
excessive salivation;
rash or itching
This is not a complete list of side effects and others may occur. Call your doctor for medical
advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Latuda Dosing Information
The recommended starting dose of Latuda is 40 mg once daily. The maximum recommended dose is 80
mg once daily. Latuda should be taken with food.
What other drugs will affect Latuda?
Before you take Latuda, tell your doctor if you regularly use other medicines that make you
sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle
relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused
by Latuda.
Also tell your doctor if you are taking any of the following medicines:
ketoconazole (Nizoral);
diltiazem (Cardizem, Dilacor);
rifampin (Rifadin, Rimactane, Rifater);
This list is not complete and other drugs may interact with Risperdal. Tell your doctor about
all medications you use. This includes prescription, over-the-counter, vitamin, and herbal
products. Do not start a new medication without telling your doctor.
Where can I get more information?
Your pharmacist can provide more information about Latuda.
gurbinder
My MedNotes
Get Updates by Email
Email me: gurbinder.sharma@gmail.com
Latuda side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives;
difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking Latuda and
call your doctor at once if you have a serious side effect such as:
fever, stiff muscles, confusion, sweating, fast or uneven heartbeats;
restless muscle movements in your eyes, tongue, jaw, or neck;
tremor (uncontrolled shaking);
fever, chills, body aches, flu symptoms;
trouble swallowing; or
feeling light-headed, fainting.
increased thirst or urination, weakness
Less serious Latuda side effects may include:
mild restlessness,agitiation, drowsiness, or tremor;
sleepiness, dreaming more than usual;
blurred vision;
abdominal pain;
dizziness or headache;
weight gain;
problems with urination;
nausea, diarrhea;
decreased appetite;
excessive salivation;
rash or itching
This is not a complete list of side effects and others may occur. Call your doctor for medical
advice about side effects. You may report side effects to http://cchrint.org
Latuda Dosing Information
The recommended starting dose of Latuda is 40 mg once daily. The maximum recommended dose is 80
mg once daily. Latuda should be taken with food.
What other drugs will affect Latuda?
Before you take Latuda, tell your doctor if you regularly use other medicines that make you
sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle
relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused
by Latuda.
Also tell your doctor if you are taking any of the following medicines:
ketoconazole (Nizoral);
diltiazem (Cardizem, Dilacor);
rifampin (Rifadin, Rimactane, Rifater); These drugs are for TB patient as well HIV /AIDS
This list is not complete and other drugs may interact with Risperdal. Tell your doctor about
all medications you use. This includes prescription, over-the-counter, vitamin, and herbal
products. Do not start a new medication without telling your doctor.
Where can I get more information?
www.cchrint.org
Your pharmacist can provide more information about Latuda.
Monday, September 27, 2010
ENHANCED MITIGATION EXPERIENCE TOOLKIT
Have you been struggling to mitigate the risks, prevent vulnerabilities from being exploited and minimize disruption of your environment of legacy products or third party applications? If yes, then
help is now available to you from Microsoft
free of charge through a tool Enhanced Mitigation Experience Toolkit (EMET). The goals for EMET are:
•Leverage the tool for vulnerabilities under active exploitation to help customers prevent themselves from being exploited.
•Give customers the ability to use newer mitigation technologies to help protect older applications that cannot be recompiled to opt into them.
•Provide a central interface to make it easier for users to manage both system and application mitigations
EMET provides users with the ability to deploy security mitigation technologies to arbitrary applications. Doing so helps to prevent vulnerabilities in those applications (especially line of business and 3rd party apps) from successfully being exploited. It also responds to requests from customers to help manage risk in older, legacy products while they are in the process of transitioning over to modern, more secure products. Beyond that it makes it easy for customers to try mitigations against any software. While EMET can be used by anybody, it is primarily targeted at protecting applications on machines that are at high risk for attack. It helps you to harden applications be it line of business applications on backend servers or browsers on the desktops.
I am sure you would be interested in this tool and you can click here to download the tool free of charge! Microsoft has also put together a video for you. The video gives an even more in-depth look at some of the security mitigations offered by the tool. You can watch the video online here.
EMET provides a total of six mitigations:-
•Dynamic Data Execution Prevention (DEP) - DEP has been available since Windows XP. However, current configuration options don't allow applications to be opted in on an individual basis unless they are compiled with a special flag. EMET allows applications compiled without that flag to also be opted.
•Structure Exception Handler Overwrite Protection (SEHOP) - This protects against currently the most common technique for exploiting stack overflows in Windows. This mitigation has shipped with Windows since Windows Vista SP1. Recently with Windows 7, the ability to turn it on and off per process was added. With EMET, Microsoft provides the Windows 7 capabilities on any platform back though Windows XP.
•Heap Spray Allocation - When an exploit runs, it often cannot be sure of the address where its shellcode resides and must make a case when taking control of the instruction pointer. To increase the odds of success, most exploits now use heapspray techniques to place copies of their shellcode at as many memory locations as possible. This mitigation blocks the use of addresses most common in today's exploits.
•Null Page Allocation - This is similar technology to the heap spray allocation, but designed to prevent potential null dereference issues in usermode. Currently there are no known ways to exploit them and thus this is a defense in depth mitigation technology.
•Export Address Table Access Filtering - This mitigation is designed to break nearly all shell code in use today. Before a piece of shellcode can do anything useful, it generally has to locate
EMET provides a total of six mitigations:-
•Dynamic Data Execution Prevention (DEP) - DEP has been available since Windows XP. However, current configuration options don't allow applications to be opted in on an individual basis unless they are compiled with a special flag. EMET allows applications compiled without that flag to also be opted.
•Structure Exception Handler Overwrite Protection (SEHOP) - This protects against currently the most common technique for exploiting stack overflows in Windows. This mitigation has shipped with Windows since Windows Vista SP1. Recently with Windows 7, the ability to turn it on and off per process was added. With EMET, Microsoft provides the Windows 7 capabilities on any platform back though Windows XP.
•Heap Spray Allocation - When an exploit runs, it often cannot be sure of the address where its shellcode resides and must make a case when taking control of the instruction pointer. To increase the odds of success, most exploits now use heapspray techniques to place copies of their shellcode at as many memory locations as possible. This mitigation blocks the use of addresses most common in today's exploits.
•Null Page Allocation - This is similar technology to the heap spray allocation, but designed to prevent potential null dereference issues in usermode. Currently there are no known ways to exploit them and thus this is a defense in depth mitigation technology.
•Export Address Table Access Filtering - This mitigation is designed to break nearly all shell code in use today. Before a piece of shellcode can do anything useful, it generally has to locate windows APIs first. This mitigation blocks a common current technique shellcode uses to do this.
•Mandatory Address Space Layout Randomization (ASLR) - ASLR randomizes the addresses where modules are loaded to help prevent an attacker from leveraging data at predictable locations. The problem with this is that all modules have to use a compile time flag to opt into this. With EMET, we force modules to be loaded at randomized addresses for a target process regardless of the flags it was compiled with.
I would encourage you to go ahead and use this tool, harden your applications and minimize the disruptions in your environment.
Sanjay Bahl is the Chief Security Officer for Microsoft Corporation (India) Pvt. Ltd., and is a member of various security committees at national and International level.
What is the purpose of this alert?
This alert is to notify you that Microsoft has released Security Advisory 2416728 - Vulnerability in ASP.NET Could Allow Information Disclosure -- on September 17, 2010.
Summary
Microsoft is investigating a new public report of a vulnerability in ASP.NET. An attacker who exploited this vulnerability could view data, such as the View State, which was encrypted by the target server, or read data from files on the target server, such as web.config. This would allow the attacker to tamper with the contents of the data. By sending back the altered contents to an affected server, the attacker could observe the error codes returned by the server. We are not aware of attacks that try to use the reported vulnerabilities or of customer impact at this time.
We are actively working with partners in our Microsoft Active Protections Program (MAPP) to provide information that they can use to provide broader protections to customers.
Upon completion of this investigation, Microsoft will take the appropriate action to help protect our customers. This may include providing a security update through our monthly release process or providing an out-of-cycle security update, depending on customer needs.
Mitigating Factors
•Microsoft has not identified any mitigations for this vulnerability.
Operating SystemComponent
Windows XP
Windows XP Media Center Edition 2005 and Windows XP Tablet PC Edition 2005 Microsoft .NET Framework 1.0 Service Pack 3
Windows XP Service Pack 3 Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows XP Professional x64 Edition Service Pack 2 Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2003
Windows Server 2003 Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2003 x64 Edition Service Pack 2 Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2003 with SP2 for Itanium-based SystemsMicrosoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Vista
Windows Vista Service Pack 1Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Vista Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Vista x64 Edition Service Pack 1Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Vista x64 Edition Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008
Windows Server 2008 for 32-bit SystemsMicrosoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for 32-bit Systems and Windows Server 2008 for 32-bit Systems Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for x64-based SystemsMicrosoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for x64-based Systems and Windows Server 2008 for x64-based Systems Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for Itanium-based SystemsMicrosoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for Itanium-based Systems Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows 7
Windows 7 for 32-bit SystemsMicrosoft .NET Framework 3.5.1
Microsoft .NET Framework 4.0
Windows 7 for x64-based SystemsMicrosoft .NET Framework 3.5.1
Microsoft .NET Framework 4.0
Windows Server 2008 R2
Windows Server 2008 R2 for x64-based Systems Microsoft .NET Framework 3.5.1
Microsoft .NET Framework 4.0
Windows Server 2008 R2 for Itanium-based systems Microsoft .NET Framework 3.5.1
Microsoft .NET Framework 4.0
Recommendations
Review Microsoft Security Advisory 2416728 for an overview of the issue, details on affected components, mitigating factors, workarounds, suggested actions, frequently asked questions (FAQs), and links to additional resources.
Customers who believe they are affected can contact Customer Service and Support (CSS) in North America for help with security update issues or viruses at no charge using the PC Safety line (866) PCSAFETY. International customers can contact Customer Service and Support by using any method found at http://www.microsoft.com/protect/worldwide/default.mspx.
Additional Resources
•Microsoft Advisory 2416728 - Vulnerability in ASP.NET Could Allow Information Disclosure
•Microsoft Security Response Center (MSRC) Blog
•Microsoft Security Research & Defense (SRD) Blog
•Microsoft Malware Protection Center (MMPC) Blog
Regarding Information Consistency
We strive to provide you with accurate information in static (this mail) and dynamic (web-based) content. Microsoft's security content posted to the Web is occasionally updated to reflect late-breaking information. If this results in an inconsistency between the information here and the information in Microsoft's web-based security content, the information in Microsoft's web-based security content is authoritative.
Thank you,
Microsoft CSS Security Team
Sincerely
Gurbinder Sharma
Partner Microsoft Online
help is now available to you from Microsoft
free of charge through a tool Enhanced Mitigation Experience Toolkit (EMET). The goals for EMET are:
•Leverage the tool for vulnerabilities under active exploitation to help customers prevent themselves from being exploited.
•Give customers the ability to use newer mitigation technologies to help protect older applications that cannot be recompiled to opt into them.
•Provide a central interface to make it easier for users to manage both system and application mitigations
EMET provides users with the ability to deploy security mitigation technologies to arbitrary applications. Doing so helps to prevent vulnerabilities in those applications (especially line of business and 3rd party apps) from successfully being exploited. It also responds to requests from customers to help manage risk in older, legacy products while they are in the process of transitioning over to modern, more secure products. Beyond that it makes it easy for customers to try mitigations against any software. While EMET can be used by anybody, it is primarily targeted at protecting applications on machines that are at high risk for attack. It helps you to harden applications be it line of business applications on backend servers or browsers on the desktops.
I am sure you would be interested in this tool and you can click here to download the tool free of charge! Microsoft has also put together a video for you. The video gives an even more in-depth look at some of the security mitigations offered by the tool. You can watch the video online here.
EMET provides a total of six mitigations:-
•Dynamic Data Execution Prevention (DEP) - DEP has been available since Windows XP. However, current configuration options don't allow applications to be opted in on an individual basis unless they are compiled with a special flag. EMET allows applications compiled without that flag to also be opted.
•Structure Exception Handler Overwrite Protection (SEHOP) - This protects against currently the most common technique for exploiting stack overflows in Windows. This mitigation has shipped with Windows since Windows Vista SP1. Recently with Windows 7, the ability to turn it on and off per process was added. With EMET, Microsoft provides the Windows 7 capabilities on any platform back though Windows XP.
•Heap Spray Allocation - When an exploit runs, it often cannot be sure of the address where its shellcode resides and must make a case when taking control of the instruction pointer. To increase the odds of success, most exploits now use heapspray techniques to place copies of their shellcode at as many memory locations as possible. This mitigation blocks the use of addresses most common in today's exploits.
•Null Page Allocation - This is similar technology to the heap spray allocation, but designed to prevent potential null dereference issues in usermode. Currently there are no known ways to exploit them and thus this is a defense in depth mitigation technology.
•Export Address Table Access Filtering - This mitigation is designed to break nearly all shell code in use today. Before a piece of shellcode can do anything useful, it generally has to locate
EMET provides a total of six mitigations:-
•Dynamic Data Execution Prevention (DEP) - DEP has been available since Windows XP. However, current configuration options don't allow applications to be opted in on an individual basis unless they are compiled with a special flag. EMET allows applications compiled without that flag to also be opted.
•Structure Exception Handler Overwrite Protection (SEHOP) - This protects against currently the most common technique for exploiting stack overflows in Windows. This mitigation has shipped with Windows since Windows Vista SP1. Recently with Windows 7, the ability to turn it on and off per process was added. With EMET, Microsoft provides the Windows 7 capabilities on any platform back though Windows XP.
•Heap Spray Allocation - When an exploit runs, it often cannot be sure of the address where its shellcode resides and must make a case when taking control of the instruction pointer. To increase the odds of success, most exploits now use heapspray techniques to place copies of their shellcode at as many memory locations as possible. This mitigation blocks the use of addresses most common in today's exploits.
•Null Page Allocation - This is similar technology to the heap spray allocation, but designed to prevent potential null dereference issues in usermode. Currently there are no known ways to exploit them and thus this is a defense in depth mitigation technology.
•Export Address Table Access Filtering - This mitigation is designed to break nearly all shell code in use today. Before a piece of shellcode can do anything useful, it generally has to locate windows APIs first. This mitigation blocks a common current technique shellcode uses to do this.
•Mandatory Address Space Layout Randomization (ASLR) - ASLR randomizes the addresses where modules are loaded to help prevent an attacker from leveraging data at predictable locations. The problem with this is that all modules have to use a compile time flag to opt into this. With EMET, we force modules to be loaded at randomized addresses for a target process regardless of the flags it was compiled with.
I would encourage you to go ahead and use this tool, harden your applications and minimize the disruptions in your environment.
Sanjay Bahl is the Chief Security Officer for Microsoft Corporation (India) Pvt. Ltd., and is a member of various security committees at national and International level.
What is the purpose of this alert?
This alert is to notify you that Microsoft has released Security Advisory 2416728 - Vulnerability in ASP.NET Could Allow Information Disclosure -- on September 17, 2010.
Summary
Microsoft is investigating a new public report of a vulnerability in ASP.NET. An attacker who exploited this vulnerability could view data, such as the View State, which was encrypted by the target server, or read data from files on the target server, such as web.config. This would allow the attacker to tamper with the contents of the data. By sending back the altered contents to an affected server, the attacker could observe the error codes returned by the server. We are not aware of attacks that try to use the reported vulnerabilities or of customer impact at this time.
We are actively working with partners in our Microsoft Active Protections Program (MAPP) to provide information that they can use to provide broader protections to customers.
Upon completion of this investigation, Microsoft will take the appropriate action to help protect our customers. This may include providing a security update through our monthly release process or providing an out-of-cycle security update, depending on customer needs.
Mitigating Factors
•Microsoft has not identified any mitigations for this vulnerability.
Operating SystemComponent
Windows XP
Windows XP Media Center Edition 2005 and Windows XP Tablet PC Edition 2005 Microsoft .NET Framework 1.0 Service Pack 3
Windows XP Service Pack 3 Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows XP Professional x64 Edition Service Pack 2 Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2003
Windows Server 2003 Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2003 x64 Edition Service Pack 2 Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2003 with SP2 for Itanium-based SystemsMicrosoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Vista
Windows Vista Service Pack 1Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Vista Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Vista x64 Edition Service Pack 1Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Vista x64 Edition Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008
Windows Server 2008 for 32-bit SystemsMicrosoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for 32-bit Systems and Windows Server 2008 for 32-bit Systems Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for x64-based SystemsMicrosoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for x64-based Systems and Windows Server 2008 for x64-based Systems Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for Itanium-based SystemsMicrosoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows Server 2008 for Itanium-based Systems Service Pack 2Microsoft .NET Framework 1.1 Service Pack 1
Microsoft .NET Framework 2.0 Service Pack 2
Microsoft .NET Framework 3.5 Service Pack 1
Microsoft .NET Framework 4.0
Windows 7
Windows 7 for 32-bit SystemsMicrosoft .NET Framework 3.5.1
Microsoft .NET Framework 4.0
Windows 7 for x64-based SystemsMicrosoft .NET Framework 3.5.1
Microsoft .NET Framework 4.0
Windows Server 2008 R2
Windows Server 2008 R2 for x64-based Systems Microsoft .NET Framework 3.5.1
Microsoft .NET Framework 4.0
Windows Server 2008 R2 for Itanium-based systems Microsoft .NET Framework 3.5.1
Microsoft .NET Framework 4.0
Recommendations
Review Microsoft Security Advisory 2416728 for an overview of the issue, details on affected components, mitigating factors, workarounds, suggested actions, frequently asked questions (FAQs), and links to additional resources.
Customers who believe they are affected can contact Customer Service and Support (CSS) in North America for help with security update issues or viruses at no charge using the PC Safety line (866) PCSAFETY. International customers can contact Customer Service and Support by using any method found at http://www.microsoft.com/protect/worldwide/default.mspx.
Additional Resources
•Microsoft Advisory 2416728 - Vulnerability in ASP.NET Could Allow Information Disclosure
•Microsoft Security Response Center (MSRC) Blog
•Microsoft Security Research & Defense (SRD) Blog
•Microsoft Malware Protection Center (MMPC) Blog
Regarding Information Consistency
We strive to provide you with accurate information in static (this mail) and dynamic (web-based) content. Microsoft's security content posted to the Web is occasionally updated to reflect late-breaking information. If this results in an inconsistency between the information here and the information in Microsoft's web-based security content, the information in Microsoft's web-based security content is authoritative.
Thank you,
Microsoft CSS Security Team
Sincerely
Gurbinder Sharma
Partner Microsoft Online
Tuesday, September 21, 2010
VMWare Take over Suse Linux
Hi Guys
VMWare win the game of Open Source Stratgey and takes over officially the SuSe Linux . Now Wait and watch What Should Happen , After Novell's Death.Will It Effect Open Source ? or Make our life Easy.
VMWare win the game of Open Source Stratgey and takes over officially the SuSe Linux . Now Wait and watch What Should Happen , After Novell's Death.Will It Effect Open Source ? or Make our life Easy.
Saturday, September 11, 2010
THE NEAR EARTH ASTEROIDS 2010 SEP
Hi Guys These Are the Potentially Dangerous Astreoids For Our Planet .This Picture Clearly Show you how lucky we were but if one of them will change his direction due to some reason
You can see , how already they are close to earth when they pass our planet one simple technical
mistake in calculations will destroy the earth.
Wednesday, September 8, 2010
Subject: khas khas (poppy seeds) upto 20 years in jail
Yesterday only I came to know of a case from a friend of mine which is very scary. One of his friends was traveling to UK via Dubai. Unfortunately he was carrying a packet of Khas Khas which is a commonly used spice in some Indian curries and sweets. Khas Khas is also known as poppy seed which can be sprouted to grow narcotics (afeem etc.).
This innocent person did not know that recently the laws in UAE and other Gulf countries have been revised and carrying Khas Khas is punishable with minimum 20 years of imprisonment or even worse with death penalty. Currently, the person is in a jail in Dubai for the last two weeks. His friends are frantically trying hard for his release but are finding that this has become a very very serious case. Lawyers are asking huge fees amounting to AED 100,000 even to appear in the court to plead for his innocence.
Please forward this email to all you know specially in Panjab. They should know the seriousness of this matter and should never ever carry even minutest quantities of the following items when traveling to Gulf countries:
1. Khas Khas whether raw, roasted or cooked.
2. Paan
3. Beetle nut (supari and its products, e.g. Paan Parag etc.)
The penalties are very severe and it could destroy the life of an innocent person.
I appeal you to create the awareness by forwarding this email to all you know.
Thanks and Best Regards
Gurbinder Sharma
CCHR
This innocent person did not know that recently the laws in UAE and other Gulf countries have been revised and carrying Khas Khas is punishable with minimum 20 years of imprisonment or even worse with death penalty. Currently, the person is in a jail in Dubai for the last two weeks. His friends are frantically trying hard for his release but are finding that this has become a very very serious case. Lawyers are asking huge fees amounting to AED 100,000 even to appear in the court to plead for his innocence.
Please forward this email to all you know specially in Panjab. They should know the seriousness of this matter and should never ever carry even minutest quantities of the following items when traveling to Gulf countries:
1. Khas Khas whether raw, roasted or cooked.
2. Paan
3. Beetle nut (supari and its products, e.g. Paan Parag etc.)
The penalties are very severe and it could destroy the life of an innocent person.
I appeal you to create the awareness by forwarding this email to all you know.
Thanks and Best Regards
Gurbinder Sharma
CCHR
Wednesday, September 1, 2010
Infectious Disease, Critical Care Medicine, Internal Medicine
Infectious Disease, Critical Care Medicine, Internal Medicine
ISSUE: We were reminded healthcare professionals of an increased mortality risk associated with the use of the intravenous antibacterial Tygacil (tigecycline) compared to that of other drugs used to treat a variety of serious infections. The increased risk was seen most clearly in patients treated for hospital-acquired pneumonia, especially ventilator-associated pneumonia, but was also seen in patients with complicated skin and skin structure infections, complicated intra-abdominal infections and diabetic foot infections. FDA has updated sections of the Tygacil drug label to include information regarding increased mortality risk of Tygacil.
BACKGROUND: Tygacil is approved by FDA for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community acquired pneumonia. Tygacil is not approved for the treatment of hospital-acquired pneumonia (including ventilator-associated pneumonia) or diabetic foot infection. The increased risk was determined using a pooled analysis of clinical trials. See the Data Summary section of the FDA Drug Safety Communication for additional details.
RECOMMENDATION: Alternatives to Tygacil should be considered in patients with severe infections. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of this product to the FDA's MedWatch Safety Information and Adverse Event Reporting Programme.
Sincerely
Gurbinder Sharma
ISSUE: We were reminded healthcare professionals of an increased mortality risk associated with the use of the intravenous antibacterial Tygacil (tigecycline) compared to that of other drugs used to treat a variety of serious infections. The increased risk was seen most clearly in patients treated for hospital-acquired pneumonia, especially ventilator-associated pneumonia, but was also seen in patients with complicated skin and skin structure infections, complicated intra-abdominal infections and diabetic foot infections. FDA has updated sections of the Tygacil drug label to include information regarding increased mortality risk of Tygacil.
BACKGROUND: Tygacil is approved by FDA for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community acquired pneumonia. Tygacil is not approved for the treatment of hospital-acquired pneumonia (including ventilator-associated pneumonia) or diabetic foot infection. The increased risk was determined using a pooled analysis of clinical trials. See the Data Summary section of the FDA Drug Safety Communication for additional details.
RECOMMENDATION: Alternatives to Tygacil should be considered in patients with severe infections. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of this product to the FDA's MedWatch Safety Information and Adverse Event Reporting Programme.
Sincerely
Gurbinder Sharma
Subscribe to:
Posts (Atom)